What the research found
The FDA approved a subcutaneous autoinjector formulation of anifrolumab (Saphnelo Pen) in April 2026 for moderate-to-severe systemic lupus erythematosus (SLE) in adults already on standard therapy. The approval followed the TULIP-SC trial, which randomized 367 patients to weekly subcutaneous anifrolumab or placebo over 52 weeks. The subcutaneous version produced essentially identical results to the intravenous formulation tested in earlier TULIP trials: roughly 20% more patients met the primary endpoint (BICLA response), translating to about one additional responder per five treated. Patients taking higher baseline steroid doses managed meaningful reductions (down to ≤7.5 mg/day and maintained), and skin manifestations showed the strongest improvements. The drug did not robustly prevent flares and carried a modest increase in herpes zoster risk.
Why it matters for you
If you're managing SLE, this addresses a practical friction point: anifrolumab now requires weekly self-injection rather than monthly infusions. This removes logistical barriers that may have prevented some people from trying the drug, and self-administration offers better schedule flexibility.
The real value proposition centres on skin disease and steroid sparing. If your SLE significantly involves rashes, photosensitivity or other cutaneous manifestations, anifrolumab showed measurable advantage. More importantly, if you're dependent on prednisone to manage symptoms, this drug may allow you to taper down—a meaningful quality-of-life gain given steroid side effects on body composition, infection risk, and metabolic health that MyKine users typically track.
However, the mechanism behind these benefits remains murkier than initially advertised. Anifrolumab was developed on the hypothesis that blocking interferon signalling would help specifically those with high interferon activation, but the data shows benefit across the board, and non-interferon factors (like ethnicity and baseline antibody patterns) predicted response just as well. This suggests the drug's action isn't as pathway-specific as the original biology suggested—it works, but we don't fully understand why or for whom it works best.
Caveats
- Early formulation data only: TULIP-SC is the first and only trial of the subcutaneous form; real-world safety and tolerability may differ
- Modest absolute benefit: 20% response difference means 60% of treated patients don't meet the primary endpoint; individual benefit is unpredictable
- Weak flare prevention: The drug did not consistently reduce lupus flares across trials, limiting its utility for preventing disease exacerbations
- Biomarker disconnect: The interferon-signature biomarker originally intended to identify responders showed minimal predictive value, raising questions about patient selection
- Limited population: Trials excluded severe kidney disease and neuropsychiatric lupus, so effectiveness in those domains is unknown
- Injection-site reactions common: ~1 in 6 patients experienced local reactions, which may reduce long-term adherence